Systemic effects of two nasally administered glucocorticosteroids
Autor: | K.-E. Andersson, J.-Å. Wihl, S.-Å. Johansson |
---|---|
Rok vydání: | 1997 |
Předmět: |
Adult
Male Budesonide Hypothalamo-Hypophyseal System medicine.medical_specialty Adolescent Hydrocortisone medicine.drug_class medicine.medical_treatment Immunology Anti-Inflammatory Agents Pituitary-Adrenal System Urine Drug Administration Schedule Double-Blind Method Pregnenediones Internal medicine Blood plasma medicine Humans Immunology and Allergy Administration Intranasal Cross-Over Studies Dose-Response Relationship Drug business.industry Beclomethasone Middle Aged respiratory system Effective dose (pharmacology) Bronchodilator Agents Steroid hormone Endocrinology Corticosteroid Female business Glucocorticoid medicine.drug |
Zdroj: | Allergy. 52:620-626 |
ISSN: | 1398-9995 0105-4538 |
DOI: | 10.1111/j.1398-9995.1997.tb01040.x |
Popis: | Two topical corticosteroids, budesonide (BUD) and beclomethasone dipropionate (BDP), both administered as suspensions in water, were investigated in healthy volunteers regarding influence on cortisol in plasma and urine (U-cortisol) after nasal application. In the first study, single doses of 200, 400, and 800 micrograms of BDP and BUD were given at 10:00 pm. In the second study, 100, 200, and 400 micrograms were given mornings and evenings for 4 days. In the single-dose study, none of the drugs or doses showed any significant influence on cortisol in plasma. However, U-cortisol decreased significantly after BUD 400 and 800 micrograms. In the multidose study, U-cortisol values were significantly reduced after all doses of BUD and the highest dose of BDP. The compounds tested showed different ability to cause measurable systemic effects after nasal application. The clinical implication is that the prescriber, when choosing a compound, should take the application site into consideration and should also be encouraged to find the lowest effective dose. |
Databáze: | OpenAIRE |
Externí odkaz: |